Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

monoclonal antibody

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug shown to slow memory decline in confirmatory study

The findings have been described as a ‘major step forward’ for dementia research

- PMLiVE

New study finds signs of dementia could be detected nine years before diagnosis

Impairment was observed in several areas across a range of dementia-related diseases

- PMLiVE

Genentech shares positive two-year data for Evrysdi in spinal muscular atrophy study

The study enrolled the ‘broadest and most diverse’ patient population ever studied in an SMA trial

- PMLiVE

New study links omega-3 intake in midlife to reduced dementia risk

Over 2,000 people who did not have dementia or stroke took part in the study

- PMLiVE

New study finds brains of ‘superagers’ contain larger neurones in memory region

Superagers had 'significantly larger' brain cells in a region of the brain that is critical for memory

- PMLiVE

Biogen and Eisai’s lecanemab shows promise in confirmatory Alzheimer’s study

Results from the phase 3 trial showed reduction in clinical decline

- PMLiVE

Genentech and ArsenalBio join to identify successful T-cell oncology therapies

While CAR-T therapy has shown promise in blood cancers, solid tumours present additional challenges

- PMLiVE

Alzheimer’s Research UK announces ‘record’ financial performance for 2021/22

The charity was forced to put much of its activity on hold due to the COVID-19 pandemic

- PMLiVE

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

- PMLiVE

Alpha Cognition announces positive results for Alzheimer’s disease treatment

The number of people with dementia is predicted to increase to around one million by 2025, increasing to 1.6 million by 2040

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links